Tritoqualine: Difference between revisions
Created page with "{{Drugbox | IUPAC_name = 7-amino-4,5,6-triethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one | image = tritoqualine.png <..." |
m Protected "Tritoqualine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 31: | Line 31: | ||
| smiles = CCOC1=C(C(=C(C2=C1C(OC2=O)C3C4=C(C5=C(C=C4CCN3C)OCO5)OC)N)OCC)OCC | | smiles = CCOC1=C(C(=C(C2=C1C(OC2=O)C3C4=C(C5=C(C=C4CCN3C)OCO5)OC)N)OCC)OCC | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Tritoqualine''', also known as '''hypostamine''', is an [[enzyme_inhibitor|inhibitor]] of the [[enzyme]] [[histidine decarboxylase]] and therefore an atypical [[antihistamine]], used for the treatment of [[urticaria]] and allergic [[rhinitis]]<ref>[http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W8N-48N2FXH-6&_user=10&_coverDate=04%2F30%2F2003&_rdoc=1&_fmt=high&_orig=gateway&_origin=gateway&_sort=d&_docanchor=&view=c&_searchStrId=1686147202&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=31a17c7d9173195401b6ca3cd672f02d&searchtype=a Randomized, placebo controlled study of tritoqualine (hypostamine*) in the treatment of perennial allergic rhinitis]. A. Pradalier, V. Hentschel, S. Prouzeau, D. Legallais, G. Lefrançois. Revue Française d’Allergologie et d’Immunologie Clinique 43:175-179 (2003)</ref> with no known adverse effects.{{fact|date=December 2013}} | '''Tritoqualine''', also known as '''hypostamine''', is an [[enzyme_inhibitor|inhibitor]] of the [[enzyme]] [[histidine decarboxylase]] and therefore an atypical [[antihistamine]], used for the treatment of [[urticaria]] and allergic [[rhinitis]]<ref>[http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W8N-48N2FXH-6&_user=10&_coverDate=04%2F30%2F2003&_rdoc=1&_fmt=high&_orig=gateway&_origin=gateway&_sort=d&_docanchor=&view=c&_searchStrId=1686147202&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=31a17c7d9173195401b6ca3cd672f02d&searchtype=a Randomized, placebo controlled study of tritoqualine (hypostamine*) in the treatment of perennial allergic rhinitis]. A. Pradalier, V. Hentschel, S. Prouzeau, D. Legallais, G. Lefrançois. Revue Française d’Allergologie et d’Immunologie Clinique 43:175-179 (2003)</ref> with no known adverse effects.{{fact|date=December 2013}} | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist|2}} | ||
{{Antihistamines}} | {{Antihistamines}} | ||
[[Category:Phenol ethers]] | [[Category:Phenol ethers]] | ||
[[Category:Lactones]] | [[Category:Lactones]] | ||
[[Category: | [[Category:Drug]] | ||
Latest revision as of 17:22, 20 August 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C26H32N2O8 |
| Molar mass | 500.54 g/mol |
| 3D model (JSmol) | |
| |
|
WikiDoc Resources for Tritoqualine |
|
Articles |
|---|
|
Most recent articles on Tritoqualine Most cited articles on Tritoqualine |
|
Media |
|
Powerpoint slides on Tritoqualine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tritoqualine at Clinical Trials.gov Clinical Trials on Tritoqualine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tritoqualine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tritoqualine Discussion groups on Tritoqualine Patient Handouts on Tritoqualine Directions to Hospitals Treating Tritoqualine Risk calculators and risk factors for Tritoqualine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tritoqualine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Tritoqualine, also known as hypostamine, is an inhibitor of the enzyme histidine decarboxylase and therefore an atypical antihistamine, used for the treatment of urticaria and allergic rhinitis[1] with no known adverse effects.[citation needed]
References
- ↑ Randomized, placebo controlled study of tritoqualine (hypostamine*) in the treatment of perennial allergic rhinitis. A. Pradalier, V. Hentschel, S. Prouzeau, D. Legallais, G. Lefrançois. Revue Française d’Allergologie et d’Immunologie Clinique 43:175-179 (2003)
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All articles with unsourced statements
- Articles with unsourced statements from December 2013
- Articles with invalid date parameter in template
- Phenol ethers
- Lactones
- Drug